
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

http://eprints.gla.ac.uk/190686/

Deposited on: 23 July 2019
Accepted Manuscript

C9orf72 and intracerebral haemorrhage

Isabel C. Hostettler, MD, Manuel Bernal-Quiros, PhD, Andrew Wong, PhD, Nikhil Sharma, FRCP PhD, Duncan Wilson, PhD, David Seiffge, MD, Clare Shakeshaft, Msc, Hans R. Jäger, MD, Hannah Cohen, PhD, Tarek Yousry, MD, Rustam Al-Shahi Salman, PhD, Gregory Y.H. Lip, FRCP, Martin M. Brown, FRCP, Keith W. Muir, MD FRCP, David J. Werring, FRCP PhD, Henry Houlden, PhD, on behalf of the CROMIS-2 collaborators

PII: S0197-4580(19)30209-X
DOI: https://doi.org/10.1016/j.neurobiolaging.2019.07.007
Reference: NBA 10616

To appear in: Neurobiology of Aging

Received Date: 3 April 2019
Revised Date: 30 May 2019
Accepted Date: 10 July 2019


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
C9orf72 and intracerebral haemorrhage

Isabel C Hostettler MD1,2, Manuel Bernal-Quiros PhD2, Andrew Wong PhD3, Nikhil Sharma FRCP PhD4,5, Duncan Wilson PhD1, David Seiffge MD1,6,7, Clare Shakeshaft MSc1, Hans R Jäger MD8, Hannah Cohen PhD9, Tarek Youssry MD5, Rustam Al-Shahi Salman PhD10, Gregory Y H Lip FRCP11,12, Martin M Brown FRCP13, Keith W Muir MD FRCP13, David J Werring FRCP PhD1, Henry Houlden PhD2 on behalf of the CROMIS-2 collaborators

1 Stroke Research Centre, University College London, Institute of Neurology, London, UK
2 Neurogenetics Laboratory, The National Hospital of Neurology and Neurosurgery, London, UK
3 MRC Unit for Lifelong Health and Ageing at UCL, London, UK
4 Department of Neurology, The National Hospital of Neurology and Neurosurgery, London, UK
5 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology
6 Stroke Centre and Neurology, University Hospital and University Basel, Switzerland
7 Department of Neurology and Stroke Center, Inselspital, University Hospital Bern, Switzerland
8 Neuroradiological Academic Unit, Department of Brain Repair & Rehabilitation, University
9 Haemostasis Research Unit, Department of Haematology, University College London, 51 Chenies Mews, London, UK
10 Centre for Clinical Brain Sciences, School of Clinical Sciences, University of Edinburgh, Edinburgh, UK
11 Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
12 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
13 Institute of Neuroscience & Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, UK

Corresponding author: Professor Henry Houlden FRCP PhD, Head of the Laboratory of Neurogenetics, The National Hospital of Neurology and Neurosurgery and UCL Institute of Neurology, University College London, Queen Square, WC1N 3BG London, United Kingdom, Phone: +44 20 3448 3141, Email: h.houlden@ucl.ac.uk

Keywords
Intracerebral haemorrhage, C9orf72, genetics, dementia, white matter changes, imaging markers

Declaration of interest: None.

Funding: HH and ICH received funding from the Alzheimer Research UK and Dunhill Medical Trust Foundation. DJW and DW received funding from the Stroke Foundation/British Heart Foundation. This work was undertaken at UCLH/UCL which receives a proportion of funding from the Department of Health’s National Institute for Health Research (NIHR) Biomedical Research Centres funding scheme. These funding bodies had not direct involvement in this study.
Abstract

The C9orf72 GGGGCC repeat expansion has been associated with several diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD). It has also been associated with increased white matter changes in FTD as well as risk of cognitive impairment in ALS. Dementia is common both before and after intracerebral haemorrhage (ICH). Since the mechanisms of cognitive impairment in patients with ICH are uncertain, we investigated whether C9orf72 could influence dementia risk in this patient group. Therefore, we genotyped 1010 clinically characterised ICH cases and 2147 population controls in comparison with prior data of dementia and ALS cases. We did not find any association between C9orf72 repeat expansion or repeat size with ICH compared to controls or with dementia when assessing ICH patients only. The frequency of C9orf72 expansions in our series of individuals born in 1946 (2/2147) and other UK controls was age-dependent decreasing with increasing age, highlighting the high age-dependant penetrance of this expansion.

Introduction

The chromosome 9 open reading frame 72 (C9orf72) GGGGCC repeat expansion has been associated with several diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)(DeJesus-Hernandez et al., 2011; Renton et al., 2011). The number of repeats to discriminate between normal repeat and pathogenic expansion is unknown although the cut-off has been suggested at 30(Van Mossevelde et al., 2017). In patients with a pathogenic repeat expansion, the number of hexanucleotide copies can be in the thousands(DeJesus-Hernandez et al., 2011; Renton et al., 2011). C9orf72 repeat expansions have previously been associated with white matter hyperintensities in FTD as well as cognitive impairment in ALS patients(Chio et al., 2016; Mahoney et al., 2015). Brain tissue of FTD patients have demonstrated amyloid beta plaques in some cases (2/51)(Simon-Sanchez et al., 2012). C9orf72 repeat expansion may therefore influence pre-ICH dementia or an increased rate of dementia after the ICH event through similar mechanisms by acting on cerebrovascular factors such as small vessel diseases and cerebral amyloid angiopathy(Cordonnier et al., 2010; Moulin et al., 2016; Pendlebury and Rothwell, 2009; Xiong et al., 2016). We hypothesized that increasing numbers of GGGGCC repeats in absence of a pathogenic repeat expansion may be associated with or influence
pre-ICH dementia in ICH patients through a mechanism that influences small vessel disease (SVD) and cerebral amyloid angiopathy (CAA). To address this hypothesis, we genotyped 1010 clinically characterised ICH cases and 2147 controls and compared them with prior data of dementia and ALS cases.

**Methods: Study cohort:** The CROMIS-2 study was approved by the National Research Ethics Service (reference: 10/H0716/64). We included patients with available DNA who had been recruited to the CROMIS-2 (NCT02513316) ICH study(Charidimou et al., 2015). Population controls were from the Medical Research Council National Survey of Health and Development (NSHD), a socially stratified cohort of 5362 singleton births that occurred during 1 week in March 1946 in England, Scotland, and Wales(Kuh et al., 2016; Rousseau et al., 2006).

**Genotyping:** C9orf72 screening was performed as previously described using sizing and repeat primed polymerase chain reaction (PCR)(DeJesus-Hernandez et al., 2011; Renton et al., 2011). In cases of suggested expansion, we performed Southern blot(DeJesus-Hernandez et al., 2011). We evaluated the number of repeats as continuous (dominant and additive) and binary variable (dichotomized into <20 and ≥20 repeats)(Rutherford et al., 2012; Van Mossevelde et al., 2017). To evaluate for dominant effect we used the number of repeats of the longer of the 2 normal alleles and for additive effect the summed repeat number of both alleles(Rutherford et al., 2012).

**Outcome measures and procedures:** Outcome variables in patients with ICH were history of dementia, SVD burden and CAA. We analysed SVD by assessing the overall burden of SVD on CT and possible and probable CAA using the modified Boston criteria(Arba et al., 2017; Linn et al., 2010). **Statistics:** Continuous variables are presented as means and SD if normally distributed, median and IQR if not normally distributed. Categorical variables are presented as number and percentage. In a second step we adjusted the regression model for age and sex. For possible and probable CAA, we adjusted for sex only. We performed all statistical analysis in STATA 15 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp).

**Results**
We analysed C9orf72 in 3157 individuals: 1010 cases and 2147 controls (Supplementary Figure 1).

The frequency of ICH patients heterozygous for C9orf72 alleles was higher compared to controls (Supplementary Table 1 and Figure 2). See Supplementary Table 2 for an overview of allele counts.

When considering allele count, we did not observe a significant difference between cases and controls (OR 1.03, 95%CI 0.99-1.07, p=0.17 for allele 1 and OR 0.99, 95%CI 0.97-1.02, p=0.53 for allele 2).

However, when considering GGGGCC repeats as a binary variable (dichotomized into <20 or ≥20 repeats), controls more frequently had ≥20 repeats (p=0.01, supplementary Table 1). In fact, only 4 ICH patients had a repeat ≥20 (0.4%) compared to 34 controls (1.6%), none of these 4 ICH patients had a history of dementia. Two individuals had a pathogenic expansion (with >80 repeats), both of whom were from our control cohort (0.09% of NSHD population controls, supplementary Table 3 and Figure 3). No pathogenic expansion was found in the ICH cohort. In the ICH cohort a history of pre-ICH dementia was associated with age but not with repeats (supplementary Table 4) measured by dominant and additive repeat variable and homozygosity. We did not observe association between the dominant repeat variant and SVD burden (OR 0.99 per point increase, 95%CI 0.95-1.02, p=0.42) nor possible or probable CAA. None of the patients with ≥20 repeats had cognitive deficits, history of dementia or imaging markers.

Discussion

This is the first study to evaluate the influence of C9orf72 alleles in an ICH cohort where we do not report pathogenic C9orf72 repeat expansions. Controls had a higher frequency of higher repeats compared to ICH patients. We could not demonstrate an effect of number of repeats on history of dementia, SVD burden, nor CAA. We observed differences between ICH patients and controls in homozygous frequency, ICH patients more frequently heterozygous. Two controls had a pathogenic expansion (0.09%). Our findings suggest the expansion in population controls is lower than previously suggested. The absence of C9orf72 repeat expansions in the ICH cohort is likely expected due to individuals with pathogenic expansions most likely having died by the time an individual suffers from an ICH (age of ALS onset ranges around 58 year of age for carrier of the C9orf72 repeat expansion)(Chio et al., 2015; Murphy et al., 2017; Westeneng et al., 2018; Wijesekera and Leigh,
The $C9orf72$ expansion cut-off has been suggested at 30. Although cases and controls were different with regards to homozygous frequency and number of repeats, the percentage of individuals with $\geq 20$ repeats was lower in both cohorts: 0.4% in ICH patients and 1.6% in population controls compared to previous results. The control data also highlights the lower frequency of $C9orf72$ expansions in our NSHD controls (Kuh et al., 2016; Rousseau et al., 2006). Blood samples for the NSHD controls were taken when they were 53.5 years of age, therefore early death due to pathogenic expansion is unlikely causing the lower percentage of expansions (Supplemental Table 3 and Figure 3). ICH individuals with $\geq 20$ repeats did not have an increased rate of history of pre-ICH dementia. In conclusion, $C9orf72$ repeat are not associated with history of pre-ICH dementia, SVD markers or CAA in the ICH population. The prevalence of $C9orf72$ GGGGCC repeat expansion in the normal population is lower than previously reported (Rutherford et al., 2012).

REFERENCES


